Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/108377
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pereira, Ana | - |
dc.contributor.author | Fernandes, Rosa | - |
dc.contributor.author | Crisóstomo, Joana | - |
dc.contributor.author | Seiça, Raquel M. | - |
dc.contributor.author | Sena, Cristina M. | - |
dc.date.accessioned | 2023-08-28T08:46:30Z | - |
dc.date.available | 2023-08-28T08:46:30Z | - |
dc.date.issued | 2017-10-30 | - |
dc.identifier.issn | 2045-2322 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/108377 | - |
dc.description.abstract | In this study we investigate pyridoxamine (PM) and/or sulforaphane (SFN) as therapeutic interventions to determine whether activators of NFE2-related factor 2 (Nrf2) can be used in addition with inhibitors of advanced glycation end products (AGE) formation to attenuate oxidative stress and improve endothelial dysfunction in type 2 diabetes. Goto-kakizaki (GK) rats, an animal model of non-obese type 2 diabetes, were treated with or without PM and/or SFN during 8 weeks and compared with age-matched Wistar rats. At the end of the treatment, nitric oxide (NO)-dependent and independent vasorelaxation in isolated aorta and mesenteric arteries were evaluated. Metabolic profile, NO bioavailability and vascular oxidative stress, AGE and Nrf2 levels were also assessed. Diabetic GK rats presented significantly lower levels of Nrf2 and concomitantly exhibited higher levels of oxidative stress and endothelial dysfunction. PM and SFN as monotherapy were capable of significantly improving endothelial dysfunction in aorta and mesenteric arteries decreasing vascular oxidative damage, AGE and HbA1c levels. Furthermore, SFN + PM proved more effective reducing systemic free fatty acids levels, normalizing endothelial function, NO bioavailability and glycation in GK rats. Activators of Nrf2 can be used therapeutically in association with inhibitors of AGE and cross-linking formation to normalize endothelial dysfunction in type 2 diabetes. | pt |
dc.language.iso | eng | pt |
dc.publisher | Springer Nature | pt |
dc.relation | info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UID/NEU/04539/2013/PT | pt |
dc.relation | PTDC/BIM-MET/4447/2014 | pt |
dc.relation | POCI-01-0145-FEDER-016784 | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt |
dc.subject.mesh | Animals | pt |
dc.subject.mesh | Aorta | pt |
dc.subject.mesh | Diabetes Mellitus, Type 2 | pt |
dc.subject.mesh | Dietary Supplements | pt |
dc.subject.mesh | Disease Models, Animal | pt |
dc.subject.mesh | Endothelium | pt |
dc.subject.mesh | Endothelium, Vascular | pt |
dc.subject.mesh | Glycation End Products, Advanced | pt |
dc.subject.mesh | Isothiocyanates | pt |
dc.subject.mesh | Male | pt |
dc.subject.mesh | Mesenteric Arteries | pt |
dc.subject.mesh | NF-E2-Related Factor 2 | pt |
dc.subject.mesh | Nitric Oxide | pt |
dc.subject.mesh | Oxidative Stress | pt |
dc.subject.mesh | Pyridoxamine | pt |
dc.subject.mesh | Rats | pt |
dc.subject.mesh | Rats, Wistar | pt |
dc.subject.mesh | Sulfoxides | pt |
dc.subject.mesh | Vascular Diseases | pt |
dc.subject.mesh | Vasodilation | pt |
dc.title | The Sulforaphane and pyridoxamine supplementation normalize endothelial dysfunction associated with type 2 diabetes | pt |
dc.type | article | - |
degois.publication.firstPage | 14357 | pt |
degois.publication.issue | 1 | pt |
degois.publication.title | Scientific Reports | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.1038/s41598-017-14733-x | pt |
degois.publication.volume | 7 | pt |
dc.date.embargo | 2017-10-30 | * |
uc.date.periodoEmbargo | 0 | pt |
item.fulltext | Com Texto completo | - |
item.grantfulltext | open | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.openairetype | article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.project.grantno | CNC. IBILI | - |
crisitem.project.grantno | CMTS2015_2020 .: Crosstalk entre o tecido adiposo perivascular e os vasos sanguíneos na obesidade e diabetes tipo 2 | - |
crisitem.author.researchunit | CNC - Center for Neuroscience and Cell Biology | - |
crisitem.author.researchunit | CNC - Center for Neuroscience and Cell Biology | - |
crisitem.author.orcid | 0000-0001-7828-2296 | - |
crisitem.author.orcid | 0000-0002-8378-0895 | - |
crisitem.author.orcid | 0000-0002-0889-2977 | - |
Appears in Collections: | I&D IBILI - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
The-Sulforaphane-and-pyridoxamine-supplementation-normalize-endothelial-dysfunction-associated-with-type-2-diabetesScientific-Reports.pdf | 6.48 MB | Adobe PDF | View/Open |
Page view(s)
81
checked on Sep 25, 2024
Download(s)
25
checked on Sep 25, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License